CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer
Yong-Pyo Lee, Min-Sang Lee, HongSik Kim, Ji-Yeon Kim, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
Cancer Research and Treatment. 2022;54(4):1130-1137.   Published online 2022 January 17    DOI: https://doi.org/10.4143/crt.2021.1103

Excel Download

Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer
Cancer Research and Treatment. 2022;54(4):1130-1137   Crossref logo
Link1 Link2 Link3

Cost-Effectiveness Model of Pertuzumab in Combination with Trastuzumab and Docetaxel Compared with Trastuzumab in Combination with Docetaxel for the 1st Line Treatment of HER2+ Metastatic Breast Cancer in Colombia
Value in Health. 2014;17(7):A631   Crossref logo
Link1 Link2

Pertuzumab plus trastuzumab and docetaxel in HER2-positive metastatic breast cancer
Community Oncology. 2012;9(2):42-44   Crossref logo
Link1 Link2

Distichiasis in association with entropion in metastatic HER2‐positive breast cancer treated by pertuzumab, trastuzumab, and docetaxel combination chemotherapy
The Breast Journal. 2019;26(5):1004-1006   Crossref logo
Link1 Link2 Link3

Pertuzumab: A Review of Its Use for First-Line Combination Treatment of HER2-Positive Metastatic Breast Cancer
Drugs. 2013;73(13):1491-1502   Crossref logo
Link1 Link2 Link3

Invited commentary on “Neoadjuvant pertuzumab plus trastuzumab in combination with anthracycline-free chemotherapy regimen in patients with HER2 positive breast cancer: Real-world data from a single center in India”.
Cancer Treatment and Research Communications. 2021;29:100487   Crossref logo
Link1 Link2

Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
PharmacoEconomics. 2014;33(1):13-23   Crossref logo
Link1 Link2 Link3

Ado-trastuzumab for the Treatment of Metastatic HER2-Positive Breast Cancer in Patients Previously Treated with Pertuzumab
. 2021;   Crossref logo
Link1 Link2

Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival
Breast Cancer: Basic and Clinical Research. 2014;8:BCBCR.S9032   Crossref logo
Link1 Link2 Link3

Neoadjuvant pertuzumab plus trastuzumab in combination with anthracycline- free chemotherapy regimen in patients with HER2 positive breast cancer–Real-world data from a single center in India
Cancer Treatment and Research Communications. 2021;29:100483   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.